

Global Cell-Free DNA (cfDNA) Testing Market 2016 Analysis and Forecast to 2022

Wiseguyreports.com add report on "Cell-Free DNA (cfDNA) Testing Global Market - Forecast to 2022" to its research database.

PUNE, INDIA, June 10, 2016 /EINPresswire.com/ -- Cell-free DNA are small fragments of DNA circulating freely in the blood and body fluids which are utilized as a valuable biomarker to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up to new possibilities in the field of gynecology, oncology, transplantation and infectious diseases. The cell-free DNA testing global market is segmented based on the type, applications and geography. By type the market is divided into cell-free fetal DNA, circulating tumour DNA, Donor derived cell-free DNA. By application, the Cell-free DNA testing market is divided into gynecology, oncology, and transplantation.

Complete report details @ <https://www.wiseguyreports.com/reports/cell-free-dna-cfdna-testing-global-market-forecast-to-2022>



Among the Cell-free DNA testing market by test type, the cell-free fetal DNA testing market is dominating the market by occupying a largest share of XX%. The donor DNA product is expected to launch in 2017 hence CAGR is calculated from 2017-2022 which makes it the fastest growing segment with CAGR XX%. In applications, the gynecology holds the largest segment with XX% share and transplantation is the fastest growing segment with a CAGR of XX% from 2017 to 2022. Geographical wise, North America holds the largest market, with a share of XX% followed by Europe and Asia. The APAC region is the fastest growing region with a CAGR of XX% from 2015 to 2022 suggesting an array of opportunities for growth and likely to be getting into the eyes of new investors in the cell-free DNA testing market. Growth in the Asian market is attributed to rising prevalence of diseases related to lifestyle change and government initiatives in establishing innovative technologies and demand for sophisticated medical services.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/cell-free-dna-cfdna-testing-global-market-forecast-to-2022>

The cell-free DNA testing market is expected to grow steadily at a CAGR of XX% during 2015 to 2022. The factors driving the growth of this market are raising number of late pregnancies leading to high incidence rates of babies with chromosomal disorders, increasing number of life threatening cancer and infectious diseases are likely to propel the market. In addition, increasing demand for

early detection through non-invasive testing procedures, healthy growth with increase in the number of deals by collaborations and acquisitions to open an array of opportunities for the market to flourish are some of the opportunities that are propelling the growth of the market. However, lack of trained health care professionals, ethical issues related to genetic testing, lack of standardization, high cost and non affordability in low- and middle-income countries, unfavourable reimbursement policies and strict legal and regulatory guidelines are hampering the growth of the market. The threats for the Cell-free DNA testing market include the availability of alternative screening methods which will impact the existing market.

The cell-free DNA testing global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced assays to maintain their market shares. The major players in the cell-free DNA testing market include Berry Genomics Co. Ltd (China), BGI (China), Boreal Genomics (U.S), Guardant health, Inc(U.S), Inivata Limited (U.K), Illumina, Inc.(U.S.), Laboratory Corp. of America Holdings (U.S.), Lifecodexx AG (Germany), Natera, Inc. (U.S.), Personal Genome Diagnostics (U.S), Premaitha Health (U.K.), Quest Diagnostics (U.S.), Roche Holdings AG (Switzerland), Sequenom, Inc. (U.S.), Trovagene, Inc (U.S) etc.

The report provides an in depth market analysis of the above mentioned segments across the following regions:

- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/cell-free-dna-cfdna-testing-global-market-forecast-to-2022>

Table of content

1 EXECUTIVE SUMMARY	20
2 INTRODUCTION	28
2.1 KEY TAKE AWAYS	28
2.2 REPORT DESCRIPTION	28
2.3 MARKETS COVERED	30
2.4 STAKEHOLDERS	31
2.5 RESEARCH METHODOLOGY	31
2.5.1 MARKET SIZE ESTIMATION	32
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION	35
2.5.3 SECONDARY SOURCES	36
2.5.4 PRIMARY SOURCES	36
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES	37
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES	37
2.5.7 ASSUMPTIONS	38
3 MARKET ANALYSIS	40
3.1 INTRODUCTION	40
3.2 MARKET SEGMENTATION	41
3.3 FACTORS INFLUENCING MARKET	42
3.3.1 DRIVERS AND OPPORTUNITIES	42
3.3.1.1 Rising number of late pregnancies leading to high incidence rate of babies with chromosomal disorders	42
3.3.1.2 Increasing number of life threatening cancers	43
3.3.1.3 Increasing demand for early detection through non-invasive testing procedures	44
3.3.1.4 Growing healthcare awareness among people and increasing healthcare expenditure in emerging countries	45

3.3.1.5 More number of deals (acquisitions, agreements) for technology sharing	46
3.3.2 RESTRAINTS AND THREATS	46
3.3.2.1 Expensive cell-free DNA tests with less reimbursement facilities	46
3.3.2.2 Ethical issues related to genetic testing	47
3.3.2.3 Lack of skilled healthcare professionals	47
3.3.2.4 Lack of standardization	48
3.3.2.5 Strict legal and regulatory guidelines	49
3.3.2.6 Emerging alternative technologies	49
3.4 REGULATORY AFFAIRS	50
3.4.1 U.S.	50
3.4.2 EUROPE	51
3.4.3 CHINA	52
3.4.4 INDIA	52
3.4.5 JAPAN	52
3.5 PORTER'S FIVE FORCE ANALYSIS	53
3.5.1 THREAT OF NEW ENTRANTS	54
3.5.2 THREAT OF SUBSTITUTES	55
3.5.3 COMPETITIVE RIVALRY	55
3.5.4 BARGAINING POWER OF SUPPLIERS	56
3.5.5 BARGAINING POWER OF BUYERS	57
3.6 PROCESS FLOW CHART OF CELL-FREE DNA TESTS	58
3.7 PATENT TRENDS	59
3.8 MARKET SHARE ANALYSIS (NIPT) BY MAJOR PLAYERS	61
3.9 FUNDING SCENARIO	64
3.10 UPCOMING TECHNOLOGIES	70
3.11 RESEARCH USE ONLY CELL-FREE DNA TESTS	71
4 CELL-FREE DNA TESTING GLOBAL MARKET, BY TYPE	73
4.1 INTRODUCTION	73
4.2 CELL-FREE DNA PRENATAL TESTING GLOBAL MARKET, BY TEST TYPE	77
4.2.1 INTRODUCTION	77
4.2.2 CELL-FREE FETAL DNA TESTS	79
4.2.2.1 Bambni test	86
4.2.2.2 Clarigo	86
4.2.2.3 Harmony test	86
4.2.2.4 Informaseq test	87
4.2.2.5 Informed pregnancy screening	87
4.2.2.6 Iona test	88
4.2.2.7 MaterniT GENOME	88
4.2.2.8 MaterniT21 Plus test	89
4.2.2.9 Nifty test	89
4.2.2.10 Panorama test	90
4.2.2.11 Prena test	91
4.2.2.12 Prenatalis	91
4.2.2.13 QNatal Advanced test	92
4.2.2.14 SafeT21 Express test	92
4.2.2.15 Verifi test	93
4.2.2.16 VisibiliT test	93

Continued.....

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-

[USD&report_id=502798](#)

Contact US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
16468459349
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.